Groundbreaking trial to combat HIV mortality rates with low-cost antibiotic
By Yasmine Jacobs | Published Mar 5, 2024
In a groundbreaking initiative, a new trial named REVIVE is set to test the efficacy of a low-cost antibiotic in reducing mortality rates among 8,000 patients with advanced HIV undergoing or restarting anti-retroviral therapy (ART).